Dendritic cell/myeloma hybrid vaccine.
Dendritic cell (DC)-tumor fusion hybrid vaccine that facilitates antigen presentation represents a new, powerful strategy in cancer therapy. We investigated the antitumor immunity derived from vaccination of fusion hybrids between wild-type J558 or engineered J558-IL-4 myeloma cells secreting cytokine interleukin-4 (IL-4) and DCs. The design and methods for generation of mature bone marrow-derived DCs, preparation of DC/J558-IL-4 hybrid, and in vivo animal studies of DC/myeloma hybrid vaccine are described. Our data show that the fusion efficiency was approx 20% by using polyethylene glycol. Our data also show that immunization of C57BL/6 mice with engineered DC/J558-IL-4 hybrids elicited stronger J558 tumor-specific cytotoxic T-lymphocyte responses in vitro and induced more efficient protective immunity against J558 tumor challenge in vivo than DC/J558 hybrid vaccines.
Xia
Dajing
D
Sakatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada.
Chan
Tim
T
Xiang
Jim
J
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology; D019496:Cancer Vaccines / Q000138:chemical synthesis; D018929:Cell Culture Techniques / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D051379:Mice; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured
D019496:Cancer Vaccines